Dow Jones -- Spanish pharmaceutical company Zeltia SA said Thursday the U.S. Food and Drug Administration has rejected a proposal to use its Yondelis drug in combination with a Johnson & Johnson (JNJ) drug to treat women with relapsed ovarian cancer.
